Laser Photonics Receives $1.3 Million Order for Pharmaceutical Tablet Laser Drilling System

Rhea-AI Summary

Laser Photonics (NASDAQ:LASE) announced a $1.3 million order from a new international pharmaceutical customer for a CMS Laser TD-140 pharmaceutical tablet laser drilling system dated January 22, 2026. The custom TD-140 supports single-sided drilling at up to 140,000 tablets per hour and includes CO2 laser hardware, dual-vision inspection, an oscilloscope for remote diagnostics, and software designed to help meet FDA 21 CFR Part 11 electronic signature and audit-log requirements. Management said the order highlights demand in high-volume regulated manufacturing and supports an expanding sales pipeline and revenue growth prospects.

Positive

• $1.3M firm order for CMS Laser TD-140
• TD-140 capacity: 140,000 tablets/hour
• System includes FDA 21 CFR Part 11-capable software and remote diagnostics

Negative

• None.

News Market Reaction

+7.83%

19 alerts

+7.83% News Effect

+6.2% Peak in 1 hr 28 min

+$4M Valuation Impact

$54M Market Cap

0.9x Rel. Volume

On the day this news was published, LASE gained 7.83%, reflecting a notable positive market reaction. Argus tracked a peak move of +6.2% during that session. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $54M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Order value: $1.3 million Tablet throughput: 140,000 tablets per hour FDA regulation: 21 CFR Part 11

3 metrics

Order value $1.3 million CMS Laser Pharmaceutical Tablet Laser Drilling System

Tablet throughput 140,000 tablets per hour TD-140 single-sided drilling capacity

FDA regulation 21 CFR Part 11 Electronic signatures and audit logs compliance

Market Reality Check

Price: $2.34 Vol: Volume 376,534 is about 0...

normal vol

$2.34 Last Close

Volume Volume 376,534 is about 0.81x the 20-day average 466,662, not signaling unusual activity. normal

Technical Shares at $2.17 are trading below the $3.01 200-day MA and 67.95% under the 52-week high.

Peers on Argus

Momentum scanner only flagged JCSE moving down with no news, while key peers lik...

1 Down

Momentum scanner only flagged JCSE moving down with no news, while key peers like LBGJ and CVV showed modest gains and others were flat or down. This points to stock-specific drivers rather than a coordinated sector move.

Historical Context

5 past events · Latest: Jan 20 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	Finance leadership change	Neutral	-2.3%	Interim Principal Financial and Accounting Officer appointed after CFO resignation.
Jan 12	Equipment order win	Positive	-0.5%	$0.5M custom CMS Laser processing system for U.S. medical device maker.
Jan 08	Conference participation	Positive	+2.8%	Planned attendance at Capitol Hill Defense Outlook Summit with large defense budget focus.
Jan 07	Marketing leadership hire	Positive	-0.5%	Appointment of VP Marketing & Corporate Communications to drive growth strategy.
Jan 05	Equipment order win	Positive	+13.5%	Approx. $500k initial CleanTech laser cleaning order from major U.S. power utility.

Pattern Detected

Recent news skewed toward new orders and management changes. Commercial order wins sometimes produced strong gains (e.g., power utility order) but have also seen mild or negative reactions, indicating inconsistent price alignment with operational wins.

Recent Company History

Over the past month, Laser Photonics reported several commercial and corporate developments. On Jan 5, it secured an initial ~$500,000 CleanTech order from a major U.S. power utility, followed by a $0.5 million CMS Laser order from a medical device manufacturer on Jan 12. The company also expanded its leadership team with a new VP of Marketing on Jan 7 and appointed Michael Lockey as Principal Financial and Accounting Officer on Jan 20. Attendance at the 2026 Capitol Hill Defense Outlook Summit reinforced its defense focus. Today’s larger $1.3 million pharmaceutical order extends this run of regulated-market equipment wins.

Market Pulse Summary

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +7.8% in the session following this news. A strong positive reaction aligns with the pattern of investors rewarding sizable equipment wins; prior orders such as the power utility contract on Jan 5 also coincided with notable gains. The $1.3 million pharmaceutical tablet drilling system order adds to a recent string of regulated-market wins. However, the stock trades well below its $3.01 200-day MA and 67.95% under its 52-week high, and past reactions to orders have been mixed, so momentum could prove fragile if follow-on demand softens or execution risk re-emerges.

Key Terms

co2 laser, oscilloscope, fda 21 cfr part 11

3 terms

co2 laser technical

"The system combines advanced CO2 laser hardware, dual-vision inspection, and an oscilloscope"

A CO2 laser is a gas-based device that produces a concentrated infrared beam used to cut, vaporize or reshape tissue and materials; think of it as a very precise, high-energy “hot knife” for surgery and industrial work. Investors watch CO2 lasers because their sales, regulatory approvals, clinical adoption and maintenance or disposables can drive revenue and margins for medical and industrial equipment makers, and influence competitive positioning and future growth.

oscilloscope technical

"advanced CO2 laser hardware, dual-vision inspection, and an oscilloscope for remote diagnostics"

An oscilloscope is an electronic test instrument that displays how electrical signals change over time, like a seismograph that shows tremors but for voltages and currents. Investors care because companies that design, build or use complex electronics rely on oscilloscopes for product development, quality control and troubleshooting, so demand and spending on these instruments can signal R&D intensity, manufacturing health and potential revenue streams.

fda 21 cfr part 11 regulatory

"software designed to help customers meet FDA 21 CFR Part 11 requirements related to electronic signatures"

FDA 21 CFR Part 11 is a U.S. regulation that sets rules for how electronic records and signatures must be created, stored and tracked so regulators can trust them like paper records. For investors, compliance reduces regulatory and operational risk by ensuring clinical, manufacturing and quality data are reliable and auditable — think of it as a digital lock and timestamp system that helps prevent errors, fraud and costly inspection failures.

AI-generated analysis. Not financial advice.

Significant Order with New International Pharmaceutical Customer Highlights Company's Growth and Revenue Opportunity

ORLANDO, FLORIDA / ACCESS Newswire / January 22, 2026 / Laser Photonics Corporation (NASDAQ:LASE), a global leader in laser systems for industrial and defense applications, today announced that it has received a $1.3 million order for a CMS Laser Pharmaceutical Tablet Laser Drilling System from a new international pharmaceutical customer.

Laser Photonics' subsidiary CMS Laser engineers fully automated, laser-powered tablet drilling systems for full-scale, high-volume pharmaceutical manufacturing. The new order is for a custom TD-140, designed for single-sided drilling of up to 140,000 circular tablets per hour. The system combines advanced CO₂ laser hardware, dual-vision inspection, and an oscilloscope for remote diagnostics to meet the most demanding commercial production environments. CMS Laser's solutions for the medical and pharmaceutical industries incorporate software designed to help customers meet FDA 21 CFR Part 11 requirements related to electronic signatures and audit logs.

Wayne Tupuola, the Chief Executive Officer of Laser Photonics, commented: "This significant order from a new customer will meet demanding production requirements, highlighting our system's precision, reliability, and validation standards in highly regulated manufacturing. CMS Laser provides advanced solutions to pharmaceutical companies around the world, addressing a wide range of pharmaceutical needs, from high-volume tablet drilling and marking to research and development.

"We are accelerating our market position in the high-demand pharmaceutical equipment sector known for its growth and stability, securing new and repeat orders for high-precision applications worldwide. Robust demand and a pipeline of new opportunities are rapidly building momentum for us as we expand our sales and marketing infrastructure, customer engagement, and market reach. We believe we will continue to strengthen revenue and growth in the months to come as we strive to build sustainable shareholder value over the long term."

To learn more about CMS Laser's tablet drilling technology, please visit our blog.

About Laser Photonics Corporation

Laser Photonics Corporation (NASDAQ:LASE) is a global leader in laser systems for industrial and defense applications. The Company develops and manufactures advanced laser technologies used in cleaning, surface preparation, and precision material processing across demanding operating environments. Laser Photonics serves a broad range of end markets, including defense and government, aerospace, energy, maritime, automotive, and advanced manufacturing. Through a combination of internal development, strategic acquisitions, and partnerships, the Company continues to expand its product portfolio and address new applications where performance, efficiency, and environmental considerations are critical. For more information, please visit laserphotonics.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations as of the date of this press release and involve risks and uncertainties that may cause results and uses of proceeds to differ materially from those indicated by these forward-looking statements. We encourage readers to review the "Risk Factors" in our Registration Statement for a comprehensive understanding. Laser Photonics Corp. undertakes no obligation to revise or update any forward-looking statements, except as required by applicable laws or regulations, to reflect events or circumstances after the date of this press release.

Investor Relations Contact
Lucas A. Zimmerman & Ian Scargill
MZ Group - MZ North America
(262) 357-2918
LASE@mzgroup.us
www.mzgroup.us

SOURCE: Laser Photonics Corp.

View the original press release on ACCESS Newswire

FAQ

What did Laser Photonics (LASE) announce on January 22, 2026?

Laser Photonics announced a $1.3 million order for a custom CMS Laser TD-140 tablet laser drilling system from a new international pharmaceutical customer.

How many tablets per hour can the CMS Laser TD-140 drill as announced by LASE?

The announced TD-140 is designed for single-sided drilling of up to 140,000 tablets per hour.

Does the LASE TD-140 system meet pharmaceutical regulatory requirements?

The system includes software designed to help customers meet FDA 21 CFR Part 11 requirements for electronic signatures and audit logs.

What notable features did Laser Photonics highlight for the TD-140 order?

The company highlighted CO2 laser hardware, dual-vision inspection, and an oscilloscope for remote diagnostics.

Will the $1.3M order likely affect Laser Photonics' revenue growth?

The company described the order as supporting expanding demand and a growing sales pipeline, which management expects to strengthen revenue in coming months.